Terms: = Prostate cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Diagnosis
5 results:
1. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive prostate cancer.
Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
[TBL] [Abstract] [Full Text] [Related]
2. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract] [Full Text] [Related]
3. Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in prostate cancer by Bioinformatics Methods.
Li D; Hao X; Song Y
Biomed Res Int; 2018; 2018():6204128. PubMed ID: 30027097
[TBL] [Abstract] [Full Text] [Related]
4. Physical Activity and cancer Outcomes: A Precision Medicine Approach.
Friedenreich CM; Neilson HK; Farris MS; Courneya KS
Clin Cancer Res; 2016 Oct; 22(19):4766-4775. PubMed ID: 27407093
[TBL] [Abstract] [Full Text] [Related]
5. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.
Robinson D; Garmo H; Bill-Axelson A; Mucci L; Holmberg L; Stattin P
BMJ; 2013 Jun; 346():f3406. PubMed ID: 23778271
[TBL] [Abstract] [Full Text] [Related]
